ARCHIVES

Amgen Halts Phase III Trial Of Ganitumab Plus Gemcitabine

This article is from The Cancer Letter archive.

Vol. 35 No. 8 | August 31, 2012

Download PDF Visit The Full Archive

Related Articles

Nobel Laureate Gilman Prepares to Leave The Texas Cancer Agency—Can it Survive?

September 28, 2012

Assurances On Methods For Misconduct Reporting Required

December 1, 1989

Retrospective Data Clean-up Can’t Help C225 Phase II Trial; Protocol Far Too “Fuzzy”

March 8, 2002

Bill Promotes Awareness Of Pediatric Cancer Research.

September 22, 2000

Oncotype DX Cancer Test Can Predict Recurrence

November 25, 2011

In Brief: Terms Expire Next Year For Six NCAB Members, One On Panel; Fraumeni Preventative Oncology President

October 16, 1981